Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 77.0%

Neg 77% Neu 0% Pos 0%

Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $15 to $4.